Recent News

• 02.10.2026 - Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
• 02.09.2026 - Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
• 01.11.2026 - Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• 01.08.2026 - Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
• 01.07.2026 - Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
• 01.05.2026 - Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference
• 11.26.2025 - Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference
• 11.03.2025 - Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results

Recent Filings

• 02.09.2026 - 144 Report of proposed sale of securities
• 01.12.2026 - 8-K Current report
• 01.12.2026 - EX-99.1 EX-99.1
• 01.08.2026 - 8-K Current report
• 01.08.2026 - EX-99.1 EX-99.1
• 12.23.2025 - 8-K Current report
• 12.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.04.2025 - 144 Report of proposed sale of securities
• 12.04.2025 - 144 Report of proposed sale of securities